Glenmark Therapeutics Inc., USA Launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC)

Glenmark Therapeutics Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC). The product is a generic version of Pataday® Twice Daily Relief, which achieved annual sales of approximately $26.4 million in the latest 52 weeks’ period ending July 13, 2024. This launch highlights Glenmark's commitment to meeting market needs and providing high-quality over-the-counter solutions for its customers. The product is now available for purchase and more information can be found on Glenmark's official website.